688331.SH
荣昌生物
SSE · Healthcare · Biotechnology · CN
CNY 116.42
−7.24%Year over year
Reported trailing growth
- Revenue
- +76.8%
- EBITDA
- —
- EBIT
- +195.7%
- EPS
- +191.5%
- Free cash flow
- +104.0%
- Operating cash flow
- +128.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +61.5%
- EBITDA
- +181.2%
- EBIT
- +149.6%
- Net income
- +148.3%
- EPS
- +147.3%
- Free cash flow
- +89.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026